Highlights
- Imugene’s onCARlytics combination with CD19-Redirected ARTEMIS® T Cells of Estrella Biopharma, Inc. has been featured at the Annual Meeting for the Society for Immunotherapy of Cancer (SITC)
- Anthony Park, from Dr. Saul Priceman’s Lab at City of Hope, has presented the poster at the event
- onCARlytics can target triple negative breast cancer (TNBC) cell line MDA-MB-468 to generate CD19t as a target for engineered T-Cells in an MOI-dependent manner
Clinical-stage immuno-oncology company Imugene Limited (ASX:IMU) today announced that its onCARlytics (CF33-CD19) oncolytic virus in combination with Estrella Biopharma, Inc’s CD19-Redirected ARTEMIS® T cells was presented at the Annual Meeting for the Society for Immunotherapy of Cancer (SITC), held in Boston, USA on 8-12 November 2022.
The poster titled, “CF33-CD19t oncolytic virus (onCARlytics) targets hepatocellular carcinoma (HCC) and in combination with CD19- Redirected ARTEMIS® T cells results in significant tumor killing,” was presented by Dr. Anthony Park, from Dr. Saul Priceman’s lab at City of Hope, at the SITC 2022.
Image: © 2022 Kalkine Media®, Data: Company Announcement
To check the poster, you may click here.
IMU shares were trading at AU$0.195 apiece at 12:12 PM AEDT on 14 November 2022.
More to come..